EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Unmet Needs of Effective Advanced Systemic Therapies in Moderate-to-Severe Atopic Dermatitis Patients in the TARGET-DERM AD Registry

Dawn Z Eichenfield, Keith D Knapp iD, Ami Claxton, Breda Munoz, Julie M Crawford, Sanjeev Balu, Yestle Kim, Shannon Schneider, Michael A Haft, Jonathan I Silverberg iD, Diamant Thaci, Lawrence F Eichenfield und 4 weitere

Dermatitis® · 2025

DOI: 10.1089/derm.2024.0191 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Dermatitis®, 2025. Verfasst von Dawn Z Eichenfield und 15 weiteren Autor:innen. Beteiligte Einrichtung: From the Departments of Dermatology and Pediatrics, University of California San Diego, San Diego, California, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Janus Kinase Inhibitors, Biological Products. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the United States, 40–50% of patients with atopic dermatitis (AD) have moderate-to-severe disease, often necessitating advanced systemic therapies (ASTs; biologics or Janus kinase inhibitors). TARGET-DERM AD is an observational, longitudinal registry that tracks the natural history and treatment of AD, including patients with moderate-to-severe disease. Among enrollees, we defined 4 patient subgroups: AST-Naïve, AST-Retrospective (AST initiated prior to enrollment), AST-Prospective (AST initiated at or after enrollment), and AST-Failed (failed at any point). This analysis describes AST-patient demographics, treatment patterns, and longitudinal outcomes. Of 598 qualifying participants (22% adolescent, 78% adult), 34% were AST-Naive, 27% AST-Retrospective, 31% AST-Prospective, and 8% AST-Failed. Comparing the adult subgroups showed significant differences in enrollment age, and race/ethnicity, but not among adolescents. There was no significant difference in AST prescription rates. Literature-based validated thresholds were used to define unchanged or worsening for each outcome, which was combined into a single category, “lacked improvement.” At 52 weeks of AST, AST-Prospective adolescents lacked improvement on Validated Investigator’s Global Assessment of Atopic Dermatitis (vIGA-AD) (26%), body surface area (BSA) (34%), Numeric Rating Scale (NRS)-Pain (63%), and NRS-Sleep (52%); AST-Prospective adults lacked improvement on vIGA-AD (21%), BSA (51%), NRS-Pain (66%), and NRS-Sleep (60%). As one-third of participants did not progress to AST, and noteworthy proportions of patients lacked improvement, this study highlights unmet needs and treatment inadequacies in patients with moderate-to-severe AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicJanus Kinase InhibitorsBiological ProductsHumansRegistriesMaleFemaleAdultAdolescentSeverity of Illness IndexYoung AdultMiddle AgedChildLongitudinal StudiesUnited StatesProspective StudiesRetrospective Studies

Substanzen

Janus Kinase InhibitorsBiological Products

Autor:innen und Institutionen

  • From the Departments of Dermatology and Pediatrics, University of California San Diego, San Diego, California, USA.
  • Target RWE, Durham, North Carolina, USA.
  • LEO Pharma, Madison, New Jersey, USA.
  • School of Medicine and Health Sciences, George Washington University, Washington, DC, USA.
  • Comprehensive Center for Inflammation Medicine, University of Lubeck, Lubeck, Germany.
  • Eczema Treatment Center of New Jersey, East Windsor, New Jersey, USA.

ORCID-Profile: Keith D Knapp, Jonathan I Silverberg

Zitieren

APA

Eichenfield, D. Z., Knapp, K. D., Claxton, A., Munoz, B., Crawford, J. M., Balu, S., Kim, Y., Schneider, S., Haft, M. A., Silverberg, J. I., Thaci, D., Eichenfield, L. F., Bagel, J., Rhoads, J. W., Paller, A. S., & TARGET-DERM AD Investigators (2025). Unmet Needs of Effective Advanced Systemic Therapies in Moderate-to-Severe Atopic Dermatitis Patients in the TARGET-DERM AD Registry. Dermatitis®. https://doi.org/10.1089/derm.2024.0191

Vancouver

Eichenfield DZ, Knapp KD, Claxton A, Munoz B, Crawford JM, Balu S, et al. Unmet Needs of Effective Advanced Systemic Therapies in Moderate-to-Severe Atopic Dermatitis Patients in the TARGET-DERM AD Registry. Dermatitis®. 2025. doi:10.1089/derm.2024.0191

BibTeX
@article{Eichenfield2025,
  author = {Eichenfield, Dawn Z and Knapp, Keith D and Claxton, Ami and Munoz, Breda and Crawford, Julie M and Balu, Sanjeev and Kim, Yestle and Schneider, Shannon and Haft, Michael A and Silverberg, Jonathan I and Thaci, Diamant and Eichenfield, Lawrence F and Bagel, Jerry and Rhoads, Jamie W and Paller, Amy S and TARGET-DERM AD Investigators, TARGET-DERM AD Investigators},
  title = {Unmet Needs of Effective Advanced Systemic Therapies in Moderate-to-Severe Atopic Dermatitis Patients in the TARGET-DERM AD Registry},
  journal = {Dermatitis®},
  year = {2025},
  doi = {10.1089/derm.2024.0191}
}
Kostenlos starten →